REGULAR STRENGTH ANALGESIC & MUSCLE RELAXANT CAPLETS TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

IBUPROFEN; METHOCARBAMOL

から入手可能:

TEVA CANADA LIMITED

ATCコード:

M03BA53

INN（国際名）:

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

投薬量:

200MG; 500MG

医薬品形態:

TABLET

構図:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

投与経路:

ORAL

パッケージ内のユニット:

18/40

処方タイプ:

OTC

治療領域:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

製品概要:

Active ingredient group (AIG) number: 0248961001; AHFS:

認証ステータス:

CANCELLED PRE MARKET

承認日:

2015-11-25

製品の特徴

IMPORTANT: PLEASE READ
1 | P a g e
PRODUCT MONOGRAPH
REGULAR STRENGTH ANALGESIC & MUSCLE
RELAXANT CAPLETS
METHOCARBAMOL AND IBUPROFEN TABLETS
500 MG/200 MG
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED,
Date of Preparation:
30 Novopharm Court
March 5, 2013
Toronto, Canada
M1B 2K9
Control# 161027
IMPORTANT: PLEASE READ
2 | P a g e
TABLE
OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
..................................................................................................3
ADVERSE
REACTIONS..................................................................................................10
DRUG
INTERACTIONS..................................................................................................12
DOSAGE AND
ADMINISTRATION..............................................................................15
OVERDOSAGE
...............................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
...........................................................18
STORAGE AND
STABILITY.........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
......................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................22
PART II: SCIENTIFIC
INFORMATION....................................................................21
PHARMACEUTICAL
INFORMATION..........................................................................21
CLINICAL
TRIALS..........................................................................................................23
DETAILED
PHARMACOLOGY........................................